## **Europe PMC Funders Group Author Manuscript**

Br J Psychiatry. Author manuscript; available in PMC 2019 November 01.

Published in final edited form as:

Br J Psychiatry. 2019 May; 214(5): 260–268. doi:10.1192/bjp.2019.54.

# Self-management interventions for people with severe mental illness: a systematic review and meta-analysis

Dr Melanie Lean, DClinPsych\* [Trainee Clinical Psychologist] and Dr Miriam Fornells-Ambrojo, PhD [Lecturer in Clinical Psychology]

Division of Psychology and Language Sciences, UCL, London, UK

Dr Alyssa Milton, PhD [Postdoctoral Research Fellow] and

Brain and Mind Centre, University of Sydney, Sydney, Australia

Dr Brynmor Lloyd-Evans, PhD [Senior Lecturer]

Mental Health and Social Care Division of Psychiatry, UCL, London, UK

Dr Bronwyn Harrison-Stewart, DClinPsych [Research Assistant] and Dr Amina Yesufu-Udechuku, PhD [Research Associate]

Centre for Outcomes Research and Effectiveness, UCL, London, UK

Professor Tim Kendall, FRCPsych [National Clinical Director] and Mental Health NHS England, UK

Professor Sonia Johnson, DM [Professor of Social and Community Psychiatry]
Division of Psychiatry, UCL, London UK

### **Abstract**

**Background**—Self-management is intended to empower individuals in their recovery by providing the skills and confidence they need to take active steps to recognise and manage their own health problems. Evidence supports such interventions in a range of long-term physical health conditions, but a recent systematic synthesis is not available for people with severe mental health problems.

**Aims**—To evaluate the effectiveness of self-management interventions for adults with severe mental illness (SMI).

**Method**—A systematic review of randomised controlled trials was conducted. A meta-analysis of symptomatic, relapse, recovery, functioning and quality of life outcomes was conducted using Revman.

**Results—**Thirty-seven trials were included with 5790 participants. From the meta-analysis, self-management interventions conferred benefits in terms of reducing symptoms and length of

Declaration of Interests: We declare no competing interests.

<sup>\*</sup>Corresponding author: Dr Melanie Lean, Department of Psychiatry and Behavioral Sciences, Stanford University, 401 Quarry Road, Stanford, CA 94305, USA; mlean@stanford.edu.

Contributors: ML, BLE, AM, MFA, TK, AYU, BHS and SJ contributed to the design and data search strategy. ML, AM, BHS and AYU completed the literature search and data extraction. ML analysed the data. ML, BLE, AM, MFA, and SJ interpreted the data. ML and MFA contributed to the creation of the tables and figures. ML wrote the review and all authors have contributed to drafting and approved the final manuscript, and all take responsibility for its content.

admission, and improving functioning and quality of life both at the end of treatment and at follow up. Overall the effect size was small to medium. The evidence for self-management interventions on readmissions was mixed. However, self-management did have a significant effect compared to control on subjective measures of recovery such as hope and empowerment at follow up, and self-rated recovery and self-efficacy at both time points.

**Conclusion**—There is evidence that the provision of self-management interventions alongside standard care improves outcomes for people with severe mental illness. Self-management interventions should form part of the standard package of care provided to people with severe mental illness and should be prioritised in guidelines: research on best methods of implementing such interventions in routine practice is needed.

### Introduction

Self-management broadly encompasses the tasks required to successfully live with and manage the physical, social and emotional impact of a chronic condition.1 Currently, there is no universally accepted classification of self-management, though it commonly involves the provision of information and education on a condition and its treatment, collaboratively creating an individualised treatment plan, developing skills for self-monitoring symptoms and strategies to support adherence to treatment including medication, psychological techniques, lifestyle and social support. A rapid synthesis1 of self-management interventions revealed a robust evidence base for improvement in outcomes of long term conditions such as diabetes and asthma, and some evidence for interventions in stroke, hypertension and depression, along with the potential for reducing health care resource use. The synthesis concluded that inclusion of self-management should be a requirement for high quality care for all long term conditions.

A range of interventions badged as self-management are available for people with long term conditions falling under the umbrella of severe mental illness2 (schizophrenia spectrum disorders, bipolar disorder and major depression), but a recent systematic synthesis regarding their effectiveness is lacking. A 2002 review of interventions for this population identified four key elements that improved the course of illness of those with SMI: (i) providing psychoeducation about mental illness and its treatment; (ii) behavioural tailoring to facilitate medication adherence; (iii) developing a relapse prevention plan; and (iv) teaching coping strategies for persistent symptoms.3 More recently, an additional focus on service-user defined recovery and personal goals has been incorporated into self-management interventions. Through these elements, self-management interventions are thought to empower individuals by providing the knowledge and skills to enable them to make informed decisions to manage their own care,4 cope with symptoms and reduce susceptibility to relapse and reliance on services.3

To date, previous reviews of self-management interventions for SMI have focused on broad, non-specific self-management interventions such as psychoeducation;5,6 self-help;7 or been confined to specific diagnoses within the SMI population8 - predominantly schizophrenia or psychosis- which limits the findings' generalisability3 and results in the exclusion of studies which have focused on broad populations of mental health service users, even though self-

management interventions are currently intended for use by a broad group. A comprehensive systematic review and meta-analysis of self-management interventions for people with SMI has not previously been available. Empowering mental health service users and supporting them in making choices about their care are increasingly given weight among the stated goals and values of mental health services and policies: self-management interventions have potential to help these goals be achieved.

The aim of the present study is to assess the effectiveness of self-management in the typical mixed populations of people with SMI such as those found in National Health Service (NHS) secondary care settings and in community mental health services in many other systems. It will look at the effect of self-management in both the short and longer term, in relation to the following pre-specified outcomes deemed important from both a commissioning and service user perspective: symptomatic recovery; relapse prevention, reduced need for hospitalisation; self-rated recovery, functioning and quality of life.

### **Methods**

A review protocol was developed following PRISMA guidelines9 and was registered at PROSPERO (Ref: CRD42017043048).

### **Inclusion Criteria**

The research question and inclusion criteria were formulated using the PICOS (Participant, Intervention, Comparison, Outcome and Study Design.9 This widely used framework supports formulation of focused and rigorous review questions.

**Participants**—Studies were included if participants were adults aged 18 years and over and diagnosed with a Severe Mental Illness (SMI),2 that is with a clinical diagnosis 10 of schizophrenia spectrum disorders (schizoaffective disorder, delusional disorder and psychosis), bipolar disorder, major depression or studies with mixed populations of people with these diagnoses (which included those with personality disorder) using secondary care mental health services.

Intervention—Studies were included if they featured the delivery of a "self-management intervention" directly to service users that was designed to educate and equip individuals with the skills to manage symptoms, relapses and overall psychosocial functioning.11 Self-management interventions were delivered in conjunction with treatment as usual. In order to investigate the effectiveness of self-management itself, interventions with a broader focus that included self-management as only one of the intervention components were not included in the current review, unless it was possible to ascertain the specific impact of self-management. To be considered a self-management intervention for the purposes of this systematic review the intervention had to include the following three (of the four) domains identified by Mueser and Colleagues3 as effective areas of self-management:

 Psychoeducation about mental illness and its treatment (in order to make informed decisions about care);

**2.** Recognition of early warning signs of relapse and development of a relapse prevention plan;

**3.** Coping skills for dealing with persistent symptoms.

Additionally, the self-management intervention should include a recovery-focused element 11 such as setting personal goals based on an individual's own hopes for their recovery and learning how to effectively manage their illness in the context of pursuing those goals.

Strategies for medication management, the fourth domain identified by Mueser and colleagues (2002), was not considered a necessary domain for a self-management intervention to be included in the current review. Making medication management a mandatory domain was considered at odds with a recovery focused approach; however the majority of studies did include a medication management component.

**Comparison**—Studies employing either treatment as usual, however defined, or active controls were included in this review.

**Outcome**—If studies reported on any of the following prespecified outcomes they were included in the meta-analyses

- 1. Symptom-focused outcomes
- **2.** Relapse (or related service use outcomes: number and length of admissions)
- **3.** Recovery-focused outcomes (including measures of overall recovery processes and its components: self-empowerment and efficacy, social connectedness, hope, optimism and the pursuit of a meaningful life).12
- **4.** Functioning (global)
- 5. Quality of life

**Study Design**—All randomised controlled trials (RCTs) including cluster RCTs and factorial RCTs were considered for inclusion. Quasi randomised studies were excluded.

### **Exclusion Criteria**

Studies were excluded if:

- 1. The intervention had a therapeutic focus beyond that of improving an individual's self-management of their illness (e.g. cognitive remediation, cognitive behavioural therapy, basic life skills or social skills), which prevented evaluating the specific efficacy of the self-management component.
- **2.** The intervention was delivered:
  - i) to family members (either as the target recipients of the intervention or in addition to the service user participants).
  - ii) as part of, or alongside another intervention e.g. The Life GoalsProgramme when it was part of the multi-component collaborative care

model, Life Goals Collaborative Care (LG-CC)13–15 was excluded on the basis of the additional nurse care management component.

### **Search Strategy and Selection Criteria**

A systematic search for all relevant literature was conducted using a PRISMA9 search strategy of the following databases: Medline, Embase, PsychINFO, DARE and CENTRAL from their inception until 15<sup>th</sup> May 2018. The relevant parts of a published search strategy used for the NICE Schizophrenia Guidelines16 was utilised in the current study and details are included in online data supplement 1. Abstracts were screened based on the review protocol (ML) and any uncertainties were reviewed to reach a consensus (ML & MFA). Twenty percent of the full text articles assessed for eligibility (n=82) were blindly assessed to meet inclusion and exclusion criteria (MFA & AM). The few cases of disagreement were discussed and consensus reached. Additionally, a hand search of reference lists was conducted.

All abstracts were retrieved and added to Mendeley referencing software (Version 1.16.3).

### **Data Extraction and Quality Assessment**

Data were extracted and reviewed in Microsoft Excel. Characteristics of the study design, the intervention, participants and outcomes for all available data at all provided time points were extracted. Authors were contacted and asked to provide any missing data. Raw outcome data extracted from papers published prior to 2012 was kindly provided by the National Collaborating Centre for Mental Health from our group's previous work with them on the development of the NICE schizophrenia guidelines. The relevant studies and outcome data provided from the original search were then extracted according to this current review protocol and checked against the original manuscripts. When a study had three arms, we followed expert guidelines17 and combined both control groups into a single group to enable pairwise comparison. Mean values were multiplied by -1 to correct for differences in the direction of scales.

### **Assessment of Bias**

Assessment of bias was performed by two pairs of researchers (BHS and AYU; ML and AM) using the Cochrane Collaboration Risk of Bias Tool.17 Each study was rated for risk of bias due to sequence generation, allocation concealment, blinding of assessors, selective outcome reporting and incomplete data. The blinding of participants in trials of complex interventions is problematic. As such, it is assumed that blinding of participants was at high risk for all studies. Risk of bias was rated as high (weakening confidence in results), low (unlikely to seriously alter results) or unclear. Funnel plots were generated to examine publication bias in analyses with more than 10 studies.18

### Statistical Analysis

Review Manager Software (Revman 5.2) was used to conduct the meta-analyses. When outcome data was reported for more than one follow-up point, the time point closest to 1-year post intervention was used. Where more than one measure was used to report the same outcome in the same study, we prioritised the primary outcome of that study or included the

outcome more commonly reported by other studies in the analysis. On the rare event that a study reported both symptomatic relapse and readmission data, we included the readmission data in the analysis. Studies with treatment as usual and active control groups were analysed together.

### **Effect Size Calculation**

Effect sizes for continuous data were calculated as standardised mean difference, Hedges' *g*, and studies were weighted using inverse variance.17 For dichotomous outcomes we calculated risk ratios and combined studies using the Mantel-Haenszel method.17 All outcomes are reported with 95% confidence intervals (CI) using random effects modelling. If reported by studies, we used intention to treat data in our analysis.

### Heterogeneity

Heterogeneity was assessed through visual inspection of forest plots, the p value of Chi squared test (Q) and calculating the  $I^2$  statistic, which describes the percentage of the variability in effect estimates that is due to heterogeneity rather than chance.19 A p value less than 0.10 and an  $I^2$  exceeding 50% suggests substantial heterogeneity. Quantifying inconsistency across studies in this way allowed us to explore the possible reasons for heterogeneity through sensitivity analysis.

Sensitivity analyses were carried out using the one-study-removed method to examine the effect of a specific study on the pooled treatment effect. When a study was identified as substantially contributing to heterogeneity, the potential sources of clinical or methodological heterogeneity were reviewed and compared to the remaining studies to evaluate if their exclusion from the particular meta-analysis was warranted.

### Results

Of the 6486 potentially relevant citations, 82 papers were retrieved and assessed for inclusion (figure 1). Of these, 20 were excluded because they were not mental health self-management interventions (either they did not meet the three criteria for inclusion, or covered social skills training only); one study was not completed (protocol paper only); and a further 18 papers were outside of the scope of this review (i.e. self-management was delivered as part of another intervention, or included family members in the intervention). Two papers were included from a reference hand search. Thirty-seven randomised controlled trials (published across 45 full-text articles) were therefore included in the narrative synthesis. Two were not included in the meta-analyses 20,21 as they did not report usable outcomes.

### **Study Characteristics**

A detailed breakdown of the characteristics of the studies included in this review can be found in Table 1. Studies included in this review randomised a total of 5790 participants with a median sample size of 107 (range 32 to 555). The majority of studies were conducted in high income countries (k=27), with a smaller but substantial proportion in lower or

middle income countries (k = 10). The majority of studies (k=29) included participants who were currently living in the community, with eight studies recruiting from inpatient settings.

The mean age of participants was 40 years and 44% were female. In relation to clinical diagnosis, 18 studies included only participants with schizophrenia spectrum disorder and seven included only those with a diagnosis of bipolar disorder. The remaining 12 included mixed populations of participants with schizophrenia, psychosis, bipolar, major depressive disorder and personality disorder in contact with secondary mental health services.

Across the 37 studies, self-management interventions ranged broadly in duration from 1 to 52 weeks (median duration 12 weeks). Likewise, face-to-face/group contact time also ranged widely from 4 to 96 hours (median 23 hours). Most interventions were delivered in a group format, and facilitated by clinicians (k=25) or peers (k=5). The remaining interventions were delivered to participants individually, either as an online, computer-based intervention (k=2), by a clinician (k=2) or by peer (k=1). Finally, two studies used a combination of group and individual sessions facilitated by clinician. All interventions were delivered from a manualised protocol, however the depth, detail and fidelity of the intervention to the manual was not always reported in detail. All interventions were delivered in addition to treatment as usual provided in the respective settings.

Table two provides a detailed breakdown of the studies reviewed, organised by a preliminary typology of self-management interventions developed as part of this review (further details in DS2).

### **Controls**

Self-management interventions were compared to treatment as usual (TAU) in 19 studies, waiting list control conditions in three studies and the remaining 12 had active control conditions such as group counselling, occupational therapy or psychoeducation (Table 2). A further three were multi-arm studies with active and TAU control groups.

### **Outcome Measures**

The table in data supplement 3 outlines the continuous measures used in studies, categorised by outcome type. Dichotomous data were also reported. Outcome measures used across the studies were reported to be well-validated and reliable instruments. Symptom outcomes were reported on measures ranging from self-rated (The Internal State Scale (ISS) to those rated by caregivers (PECC) and those requiring a clinical interview (PANSS and BPRS). In the majority of studies, relapse was measured as an admission to hospital. A small minority of trials additionally identified relapse in participants when a score reached a cut-off point on a scale, but admission data was given precedence in the present analysis. Measures of quality of life were self-rated whereas functioning tended to be clinician rated. Measures of recovery which focused on personal recovery as opposed to clinical recovery were exclusively self-rated.

### Risk of Bias

The risk of bias summary is shown in Figure 2 and the rating for each individual study can be found in data supplement 4. Blinding of participants and personnel is generally considered to be challenging in complex interventions, so that risk of bias in this respect was rated as high in all studies except for one.59 Of note, nine studies were at a high risk of bias for selective reporting of outcomes measured, and 18 were unclear. The "other bias" category refers to whether any studies were discontinued due to adverse events or problems with the study design or acceptability of the intervention.

**Quantitative Synthesis**—Data were analysed at two time points: at the end of the treatment intervention (that is, immediately, or within two weeks) and at follow up. The median follow-up length was 41 weeks (range 4 to 104 weeks) post-treatment; 52 weeks (range 7 to 130 weeks) post randomisation. Summary results are outlined in table three below (forest plots in data supplement 5).

### **Symptoms**

Seventeen studies (n=1979) found a small but significant effect of self-management on total symptoms at post treatment (SMD= -0.43, 95% CI [-0.63 to -0.22]). At follow up, 13 studies (n= 1520) demonstrated a marked effect of self-management on total symptoms (SMD= -0.88; 95% CI [-1.19 to -0.57]). There was no significant effect on positive symptoms at post-treatment, however at follow up (K= 6; n= 771) there was a moderate effect (SMD= -0.61; 95% CI [-1.03 to -0.19]). Self-management had a small effect on negative symptoms at post treatment (SMD= -0.26, 95% CI [-0.47 to -0.05]) and a moderate effect at follow up (SMD= -0.51, 95% CI [-0.82 to -0.21]). When looking at symptoms of depression and anxiety, five studies (n= 452) favoured self-management both at end of treatment (SMD= -0.26; 95% CI [-0.51 to -0.01]) and follow up (SMD= -0.19; 95% CI [-0.33 to -0.04]; k=6; n= 964).

### Relapse/Readmission

Self-management did not have an effect on the total number of patients readmitted at either time point (SMD= 0.84, 95% CI [0.48, 1.46] and SMD=0.75, 95% CI [0.51, 1.08] respectively), however there was an effect at follow up on the mean number of readmissions (SMD= -0.92, 95% CI [-1.63 to -0.21]). A small effect (SMD= -0.26, 95% CI [-0.50 to -0.02]) was demonstrated on length of hospital admissions immediately following treatment (k=6, n= 902), while a moderate effect (SMD= -0.68, 95% CI [-1.10 to -0.25] was found at follow up (k=7, n= 908).

### **Self-rated Recovery**

In relation to overall self-rated recovery, self-management was favoured over control at both time points with a moderate effect size (SMD=-0.62; 95% CI [-1.03 to -0.22]) immediately following treatment (k=11; n=1013), and a large effect at follow up (k=7, n=1134; SMD=-0.81; 95% CI [-1.40 to -0.22]).

### **Empowerment**

At the end of treatment (k=3; n=346) self-management interventions did not increase sense of empowerment (SMD=-1.44; 95% CI [-2.97 to 0.08]), however at follow up (k=2, n= 538) there was a small but significant effect (SMD=-0.25; -0.43 to -0.07).

### Hope

Self-management did not impact hope at end of treatment (k= 2, n= 389; SMD= - 0.18; 95% CI [-0.38 to 0.01]). At follow up three studies with 967 participants showed a small but significant effect favouring self-management over control (SMD= -0.24; [-0.46 to -0.02]).

### **Self-Efficacy**

Four studies (n= 601) reporting on self-efficacy at end of treatment favoured self-management (SMD=-0.38; 95% CI [-0.62 to -0.15]). One study provided data for self-efficacy at follow up (n= 221), which also favoured self-management (SMD= - 0.34; 95% CI [-0.61 to -0.07]).

### **Functioning**

At the end of treatment (k=15, n=1948), there was evidence of a moderate effect of self-management on functioning (SMD= -0.56; 95% CI [-0.85 to -0.28]). At follow up (k=14, n=1805) this increased to a large sized effect of self-management on social and functional disability (SMD= -0.90; 95% CI [-1.34 to -0.45]).

### **Quality of Life**

Immediately following the end of the intervention, evidence from nine studies (n=863) showed a small but significant effect of self-management on participant's self-rated quality of life (SMD=-0.23; 95% CI [-0.37 to -0.10]) which was maintained at follow up (k= 7, n=980) (SMD=-0.25, 95% CI [-0.37 to -0.12]).

### Heterogeneity and Sensitivity Analyses

Seventeen of the twenty-two meta-analyses had high levels of heterogeneity as assessed by an  $I^2$  greater than 50% and/or a significant  $X^2$  test. The one-study-removed method17 was utilised to explore sources of statistical heterogeneity. Although high heterogeneity was identified in a range of meta-analyses, it did not appear to be driven by just one study. An evaluation of clinical and methodological characteristics resulted in the decision to not remove any studies. A full account of the sensitivity analysis is in data supplement 6.

### **Publication Bias**

Funnel plots were created for the six meta-analyses that had more than 10 studies (see data supplement 7). The small number of studies and participants across these studies, meant that it was difficult to discern any evident publication bias.

### **Post-Hoc Analysis**

A post-hoc sub group analysis of TAU only and active control only studies was conducted (see results table in data supplement 8). No differential pattern of outcomes between the different comparators was found.

### Discussion

This is the first comprehensive systematic review and meta-analysis evaluating self-management interventions for people with severe mental illness. The reviewed evidence suggests that self-management does confer benefits across a broad range of outcomes. Specifically, self-management has a positive impact on total symptom severity, negative symptoms and the symptoms of depression and anxiety, both at end of treatment and at 1-year follow-up. Self-management was found to impact on positive symptoms at follow up only. The effect size for self-management on total symptom severity was comparable to or better than those found in recent meta-analyses of cognitive behavioural therapy for psychosis (CBTp): pooled effect size -0.33 [95%CI: -0.47 to -0.19]65 and 0.40 [95%CI [0.252, 0.58].66 At longer term follow up (approximately 1 year post intervention) self-management had a large effect (SMD=-0.88; 95%CI [-1.19, -0.57]) although the high heterogeneity should be noted.

Despite the positive effect on symptoms, the findings were inconsistent for variables related to relapse and readmission. This was in contrast to a previous meta-analysis of self-management interventions for those with schizophrenia only8 which found a significant impact on relapse and readmission. In the present review, few studies reported relapse as an outcome and of those that did, only a small number of participants experienced relapse events which may account for the lack of effect. The paucity of data impedes making any comment on the effect of self-management on relapse. Self-management did however demonstrate a small to moderate effect in terms of reducing the average length of hospitalisation both at the end of treatment and one year follow-up.

Self-management did demonstrate a significant medium sized effect on global functioning, and a small but significant effect on quality life at both end of treatment and 1-year follow-up. Furthermore, self-management seems to confer a benefit on outcomes valued especially highly by consumers,67 that is outcomes related to personal recovery, and individual's sense of empowerment, hope and self-efficacy. A moderate to large effect on overall recovery and self-efficacy was seen at both end of treatment and follow up; the effect on the recovery related concepts of empowerment and hope were significant at follow up only.

### Methodological Limitations of Primary Studies

While all studies included in this review were randomised controlled trials, there was variation in the reporting of sequence generation, allocation concealment and, as is common in complex interventions, blinding of participants and personnel was not always consistent. The greatest cause for concern was the selective reporting of outcomes which was noted or not clearly reported in two thirds of the studies reviewed. Furthermore, the relatively small number of studies and participants in some studies, meant that it was difficult to discern any

evident publication bias. These limitations must be considered alongside the findings presented in this review to avoid an overestimate of the benefit of self-management.

### Strengths and Limitations of the Review

This review gives a broad indication of the effectiveness and potential value of self-management interventions for people with severe mental illness. A strength of this review is the generalisability of the findings to current practice. For instance, it included a diagnostically heterogeneous sample of people with SMI, representative of those on caseloads in secondary care mental health services, and included samples from a wider range of countries and cultures.

Regarding limitations, heterogeneity was found to be high across many of the meta-analyses, and while a certain amount of heterogeneity is inevitable, we have tried to mitigate this through the use of random effects modelling17. A further potential limitation is from the risk of bias quality assessment of the studies included in this review. Interestingly, readmission rates and service use outcomes were infrequently measured by studies. We recommend the inclusion of this outcome in future studies of self-management. We also encourage collection and reporting of important sample characteristics such as participants' length of illness. Fewer than half of the included studies reported on length of illness - a potential mediator of the effectiveness of self-management interventions.

The choice to pool together comparisons of self-management against TAU or against active controls in the same analyses could be criticised. A post-hoc sub group analysis of TAU only and active control only studies showed no differential pattern of outcomes between the different comparators. Arguably, TAU varies hugely among the included studies, and all of the active controls are treatments which might be available from a multi-disciplinary community mental health team. Thus, irrespective of whether TAU and active controls are combined or not, the analysis is evaluating the addition of self-management to highly varied care.

The absence of patient and public involvement (PPI) in this review is a limitation. Its inclusion would have been particularly useful in developing the operationalisation of self-management, as well as contributing to the interpretation and implications of findings from a users' perspective. A final limitation in conducting this review was the lack of consensus of how to define the concept known as self-management. Our review is based on a clear operationalisation of self-management: however, there is still substantial variation in interventions.

### Implications for Practice

While self-management for this population has been previously recommended at a guideline level,16,68 it remains to be routinely implemented at a service level. On the basis of this review, there is a strong case for including self-management as a high priority for psychosis services and generic community mental health services, alongside interventions such as CBTp or employment support. The diagnostically mixed populations in many studies may have been an impediment to identification of self-management as a high priority in guidance focused on specific groups, but our study supports recommendations from policy bodies and

service user groups that support for self-management should be at the core of care for all long-term health conditions, physical and mental69,70. Self-management interventions are relatively straightforward compared to other psychotherapeutic interventions and can be delivered across settings and in a variety of ways, including group, individual, digital, bibliotherapy or a combination, increasing potential for wide implementation. In this population they are often supported: support may be from clinicians, but also from peers, which one may hypothesise could be especially effective in empowering patients and increasing self-efficacy to manage their illness. Effective implementation of these interventions have the potential to alter the long-term course of both the mental and physical health of people with severe mental illness.

### Research Implications

In terms of future research, demonstrating whether there are clear effects on relapse and readmission is likely to require large, methodologically robust trials that include these outcomes along with cost effectiveness analysis. The high heterogeneity in this review suggests there are important differences in the content and implementation or context of self-management interventions which influence how effective they may be. There are likely a number of potential contributors: length of intervention, contact time, facilitator (clinician or peer) and type of self-management intervention (from proposed subtypes). Future intervention studies would also benefit from the inclusion of measures of potential mediators and moderators: for instance the addition of measures of cognitive outcomes in future studies will be important to assess its role in mediating improvements in functioning. Additionally, structured development of future self-management programs in conjunction with service users is recommended.71

Accordingly, there is a need to explore what forms of self-management are most effective, feasible and acceptable, and for whom. Possible study paradigms include realist evaluation of what works for whom, mechanistic studies or a broader systematic review that would have in its scope naturalistic studies using a variety of methods to look at experiences and outcomes of delivering self-management in various ways. Nevertheless, the evidence that self-management already has positive effects on a range of important outcomes is already substantial: thus research is now needed on how to overcome implementation barriers and embed self-management in a sustained and widespread way to routine care for people with long-term mental health conditions, and how to evaluate the effect of this. Implementation-evaluation designs have potential to address these questions.

### **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

### **Funding**

This paper reports work undertaken as part of the CORE Study, which is funded by the National Institute for Health Research under its Programme Grants for Applied Research programme (reference RP-PG-0109-10078). The views expressed are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health.

### References

 Taylor SJ, Pinnock H, Epiphaniou E, Pearce G, Parke HL, Schwappach A, et al. A rapid synthesis of the evidence on interventions supporting self-management for people with long-term conditions: PRISMS – Practical systematic Review of Self-Management Support for long-term conditions. Heal Serv Deliv Res. 2014; 2:1–580.

- Substance Abuse and Mental Health Services Administration (SAMHSA). The Way Forward: federal action for a system that works for all people living with SMI and SED and their families and caregivers. Interdepartmental Serious Mental Illness Coordinating Committee Full Report. 2017
- 3. Mueser KT, Corrigan PW, Hilton DW, Tanzman B, Schaub A, Gingerich S, et al. Illness Management and Recovery: a review of the research. Psychiatr Serv. 2002; 53:1272–84. [PubMed: 12364675]
- 4. Mueser KT, McGurk SR. Schizophrenia. Lancet. 2004; 363:2063-72. [PubMed: 15207959]
- 5. Zhao S, Sampson S, Xia J, Jayaram MB. Psychoeducation (brief) for people with serious mental illness. Cochrane Database Syst Rev. 2015; 4:1–117.
- Lincoln TM, Wilhelm K, Nestoriuc Y. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: A meta-analysis. Schizophr Res. 2007; 96:232–45. [PubMed: 17826034]
- Scott AJ, Webb TL, Rowse G. Self-help interventions for psychosis: A meta-analysis. Clin Psychol Rev. 2015; 39:96–112. [PubMed: 26046501]
- 8. Zou H, Li Z, Nolan MT, Arthur D, Wang H, Hu L. Self-management education interventions for persons with schizophrenia: a meta-analysis. Int J Ment Health Nurs. 2013; 22:256–71. [PubMed: 22882803]
- 9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009; 6:e1000097. [PubMed: 19621072]
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. American Psychiatric Association; 2000.
- Mueser KT, Deavers F, Penn DL, Cassisi JE. Psychosocial Treatments for Schizophrenia. Annu Rev Clin Psychol. 2013; 9:465–97. [PubMed: 23330939]
- Leamy M, Bird V, LeBoutillier C, Williams J, Slade M. Conceptual framework for personal recovery in mental health: systematic review and narrative synthesis. Br J Psychiatry. 2011; 199:445–52. [PubMed: 22130746]
- 13. Bauer MS, McBride L, Williford WO, Glick H, Kinosian B, Altshuler L, et al. Collaborative care for bipolar disorder: part I. Intervention and implementation in a randomized effectiveness trial. Psychiatr Serv. 2006; 57:927–36. [PubMed: 16816276]
- 14. Bauer MS, McBride L, Williford WO, Glick H, Kinosian B, Altshuler L, et al. Collaborative care for bipolar disorder: Part II. Impact on clinical outcome, function, and costs. Psychiatr Serv. 2006; 57:937–45. [PubMed: 16816277]
- Bauer MS, Biswas K, Kilbourne AM. Enhancing multiyear guideline concordance for bipolar disorder through collaborative care. Am J Psychiatry. 2009; 166:1244–50. [PubMed: 19797436]
- 16. National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. 2014. (https://www.nice.org.uk/guidance/cg178)
- 17. Higgins, J, Green, S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
- 18. Sterne JAC, Egger M, Smith GD. Systematic Reviews in Health Care: Investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001; 323:101–5. [PubMed: 11451790]
- Cuijpers, P. Meta-analyses in mental health research: A practical guide. Vrije Universiteit Amsterdam; 2016.
- 20. Eckman T, Wirshing W, Marder S, Liberman R, Johnston-Cronk M, Zimmerman K, et al. Techniques for training schizophrenic patients in illness self-management: A controlled trial. Am J Psychiatry. 1992; 149:1549–55. [PubMed: 1384364]

 Kopelowicz A, Wallace C, Zarate R. Teaching psychiatric inpatients to re-enter the community: a brief method of improving the continuity of care. Psychiatr Serv. 1998; 49:1313–6. [PubMed: 9779901]

- 22. Atkinson JM, Coia DA, Gilmour WH, Harper JP. The impact of education groups for people with schizophrenia on social functioning and quality of life. Br J Psychiatry. 1996; 168:199–204. [PubMed: 8837910]
- Barbic S, Krupa T, Armstrong I. A randomized controlled trial of the effectiveness of a modified recovery workbook program: preliminary findings. Psychiatr Serv. 2009; 60:491–7. [PubMed: 19339324]
- 24. Chien WT, Lee IYM. The mindfulness-based psychoeducation program for chinese patients with schizophrenia. Psychiatr Serv. 2013; 64:376–9. [PubMed: 23412024]
- Chien WT, Thompson DR. Effects of a mindfulness-based psychoeducation programme for Chinese patients with schizophrenia: 2-year follow-up. Br J Psychiatry. 2014; 205:52–9. [PubMed: 24809397]
- Chien WT, Bressington D, Yip A, Karatzias T. An international multi-site, randomized controlled trial of a mindfulness-based psychoeducation group programme for people with schizophrenia. Psychol Med. 2017; 47:2081–96. [PubMed: 28374661]
- 27. Cook JA, Copeland ME, Jonikas JA, Hamilton MM, Razzano LA, Grey DD, et al. Results of a randomized controlled trial of mental illness self-management using wellness recovery action planning. Schizophr Bull. 2011; 38:881–91. [PubMed: 21402724]
- Cook JA, Copeland ME, Floyd CB, Jonikas JA, Hamilton MM, Razzano LA, et al. A Randomized Controlled Trial of Effects of Wellness Recovery Action Planning on Depression, Anxiety, and Recovery. Psychiatr Serv. 2012; 63:541–7. [PubMed: 22508435]
- Jonikas JA, Grey DD, Copeland ME, Razzano LA, Hamilton MM, Floyd CB, et al. Improving propensity for patient self-advocacy through wellness recovery action planning: Results of a randomized controlled trial. Community Ment Health J. 2013; 49:260–9. [PubMed: 22167660]
- 30. Cook JA, Steigman P, Pickett S, Diehl S, Fox A, Shipley P, et al. Randomized controlled trial of peer-led recovery education using Building Recovery of Individual Dreams and Goals through Education and Support (BRIDGES). Schizophr Res. 2012; 136:36–42. [PubMed: 22130108]
- 31. Pickett SA, Diehl SM, Steigman PJ, Prater JD, Fox A, Shipley P, et al. Consumer empowerment and self-advocacy outcomes in a randomized study of peer-led education. Community Ment Health J. 2012; 48:420–30. [PubMed: 22460927]
- 32. Dalum HS, Waldemar AK, Korsbek L, Hjorthøj C, Mikkelsen JH, Thomsen K, et al. Illness management and recovery: Clinical outcomes of a randomized clinical trial in community mental health centers. PLoS One. 2018; 13:1–15.
- 33. Dalum HS, Waldemar AK, Korsbek L, Hjorthoj C, Mikkelsen JH, Thomsen K, et al. Participants' and staffs' evaluation of the Illness Management and Recovery program: a randomized clinical trial. J Ment Heal. 2018; 27:30–7.
- 34. Färdig R, Lewander T, Melin L, Folke F, Fredriksson A. A randomized controlled trial of the illness management and recovery program for persons with schizophrenia. Psychiatr Serv. 2011; 62:606–12. [PubMed: 21632728]
- 35. Hasson-Ohayon I, Roe D, Kravetz S. A randomized controlled trial of the effectiveness of the illness management and recovery program. Psychiatr Serv. 2007; 58:1461–6. [PubMed: 17978257]
- 36. Levitt AJ, Mueser KT, Degenova J, Lorenzo J, Bradford-Watt D, Barbosa A, et al. Randomized controlled trial of illness management and recovery in multiple-unit supportive housing. Psychiatr Serv. 2009; 60:1629–36. [PubMed: 19952153]
- 37. Lin EC-L, Chin Hong C, Wen-Chuan S, Mei-Feng L, Shujen S, Mueser KT, et al. A randomized controlled trial of an adapted Illness Management and Recovery program for people with Schizophrenia awaiting discharge from a psychiatric hospital. Psychiatr Rehabil J. 2013; 36:243–9. [PubMed: 24320832]
- 38. Monroe-DeVita M, Morse G, Mueser KT, McHugo GJ, Xie H, Hallgren KA, et al. Implementing Illness Management and Recovery Within Assertive Community Treatment: A Pilot Trial of Feasibility and Effectiveness. Psychiatr Serv. 2018; 69:562–71. [PubMed: 29446335]

39. Perry A, Tarrier N, Morriss R, Mccarthy E, Limb K. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ. 1999; 318:149–53. [PubMed: 9888904]

- 40. Sajatovic M, Davies MA, Ganocy SJ, Bauer MS, Cassidy KA, Hays RW, et al. A comparison of the life goals program and treatment as usual for individuals with bipolar disorder. Psychiatr Serv. 2009; 60:1182–9. [PubMed: 19723732]
- 41. Salyers MP, McGuire AB, Rollins AL, Bond GR, Mueser KT, MacY VR. Integrating assertive community treatment and illness management and recovery for consumers with severe mental illness. Community Ment Health J. 2010; 46:319–29. [PubMed: 20077006]
- 42. Shon K-H, Park S-S. Medication and symptom management education program for the rehabilitation of psychiatric patients in Korea: The effects of promoting schedule on self-efficacy theory. Yonsei Med J. 2002; 43:579–89. [PubMed: 12402370]
- 43. Smith DJ, Griffiths E, Poole R, di Florio A, Barnes E, Kelly MJ, et al. Beating Bipolar: Exploratory trial of a novel internet-based psychoeducational treatment for bipolar disorder. Bipolar Disord. 2011; 13:571–7. [PubMed: 22017225]
- 44. Tan CHS, Ishak RB, Lim TXG, Marimuthusamy P, Kaurss K, Leong JYJ. Illness management and recovery program for mental health problems: reducing symptoms and increasing social functioning. J Clin Nurs. 2017; 26:3471–85. [PubMed: 28032918]
- 45. Todd NJ, Solis-Trapala I, Jones SH, Lobban FA. An online randomised controlled trial to assess the feasibility, acceptability and potential effectiveness of 'Living with Bipolar': A web-based self-management intervention for Bipolar Disorder. Trial design and protocol. Contemp Clin Trials. 2012; 33:679–88. [PubMed: 22387150]
- 46. Todd NJ, Jones SH, Hart A, Lobban FA. A web-based self-management intervention for Bipolar Disorder 'living with bipolar': a feasibility randomised controlled trial. J Affect Disord. 2014; 169:21–9. [PubMed: 25129531]
- 47. Torrent C, Bonnin M Ph D, Martínez-arán A Ph D, Valle J, et al. Efficacy of Functional Remediation in Bipolar Disorder: A Multicenter Randomized Controlled Study. Am J Psychiatry. 2013; 170:852–9. [PubMed: 23511717]
- 48. Van Gestel-Timmermans H, Brouwers EPM, van Assen MaLM, van Nieuwenhuizen C. Effects of a Peer-Run Course on Recovery From Serious Mental Illness: A Randomized Controlled Trial. Psychiatr Serv. 2012; 63:54–60. [PubMed: 22227760]
- 49. Vreeland B, Minsky S, Yanos PT, Menza M, Gara M, Kim E, et al. Efficacy of the team solutions program for educating patients about illness management and treatment. Psychiatr Serv. 2006; 57:822–8. [PubMed: 16754759]
- 50. Wang LQ, Chien WT, Yip LK, Karatzias T. A randomized controlled trial of a mindfulness-based intervention program for people with schizophrenia: 6-month follow-up. Neuropsychiatr Dis Treat. 2016; 12:3097–110. [PubMed: 27994466]
- 51. Zhou B, Zhang P, Gu Y. Effectiveness of self-management training in community residents with chronic schizophrenia: a single-blind randomized controlled trial in Shanghai, China. Shanghai Arch Psychiatry. 2014; 26:81–7. [PubMed: 25092953]
- 52. Anzai N, Yoneda S, Kumagai N, Nakamura Y, Ikebuchi E, Liberman RP. Training persons with Schizophrenia in illness self-management: a randomized controlled trial in Japan. Psychiatr Serv. 2002; 53:545–7. [PubMed: 11986501]
- 53. Chan SH-W, Lee SW-K, Chan IW-M. TRIP: a psycho-educational programme in Hong Kong for people with schizophrenia. Occup Ther Int. 2007; 14:86–98. [PubMed: 17623381]
- 54. Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry. 2003; 60:402–7. [PubMed: 12695318]
- 55. Colom F, Vieta E, Sánchez-Moreno J, Palomino-Otiniano R, Reinares M, Goikolea JM, et al. Group psychoeducation for stabilised bipolar disorders: 5-Year outcome of a randomised clinical trial. Br J Psychiatry. 2009; 194:260–5. [PubMed: 19252157]
- 56. Cook JA, Jonikas JA, Hamilton MM, Goldrick V, Steigman PJ, Grey DD, et al. Impact of Wellness Recovery Action Planning on service utilization and need in a randomized controlled trial. Psychiatr Rehabil J. 2013; 36:250–7. [PubMed: 24320833]

57. Mackain SJ, Smith TE, Wallace CW, Kopelowicz A. Evaluation of a community re-entry program. Int Rev Psychiatry. 1998; 10:76–83.

- 58. Proudfoot J, Parker G, Hyett M, Manicavasagar V, Smith M, Grdovic S, et al. Web-based bipolar disorder program. Aust N Z J Psychiatry. 2007; 41:903–9. [PubMed: 17924243]
- Proudfoot J, Parker G, Manicavasagar V, Hadzi-Pavlovic D, Whitton A, Nicholas J, et al. Effects of adjunctive peer support on perceptions of illness control and understanding in an online psychoeducation program for bipolar disorder: A randomised controlled trial. J Affect Disord. 2012; 142:98–105. [PubMed: 22858215]
- 60. Salyers MP, McGuire AB, Kukla M, Fukui S, Lysaker PH, Mueser KT. A randomized controlled trial of illness management and recovery with an active control group. Psychiatr Serv. 2014; 65:1005–11. [PubMed: 24733680]
- 61. Schaub A, Mueser KT, von Werder T, Engel R, Moller HJ, Falkai P. A randomized controlled trial of group Coping-Oriented Therapy vs Supportive Therapy in Schizophrenia: results of a 2-year follow-up. Schizophr Bull. 2016; 42(Suppl 1):S71–80. [PubMed: 27460620]
- 62. Wirshing DA, Guzik LH, Zorick TS, Pierre JM, Resnick SA, Goldstein D, et al. Community reentry program training module for schizophrenic inpatients improves treatment outcomes. Schizophr Res. 2006; 87:338–9. [PubMed: 16844344]
- 63. Xiang YT, Weng YZ, Li WY, Gao L, Chen GL, Xie L, et al. Training patients with schizophrenia with the community re-entry module: A controlled study. Soc Psychiatry Psychiatr Epidemiol. 2006; 41:464–9. [PubMed: 16565915]
- 64. Xiang YT, Weng YZ, Li WY, Gao L, Chen GL, Xie L, et al. Efficacy of the community re-entry module for patients with schizophrenia in Beijing, China: Outcome at 2-year follow-up. Br J Psychiatry. 2007; 190:49–56. [PubMed: 17197656]
- 65. Jauhar S, McKenna PJ, Radua J, Fung E, Salvador R, Laws KR. Cognitive-behavioural therapy for the symptoms of schizophrenia: Systematic review and meta-analysis with examination of potential bias. Br J Psychiatry. 2014; 204:20–9. [PubMed: 24385461]
- 66. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: Effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008; 34:523–37. [PubMed: 17962231]
- 67. Slade, M, Longden, E. The empirical evidence about mental health and recovery: how likely, how long, what helps?. Victoria: MI Fellowship; 2015.
- 68. National Institute for Health and Care Excellence (NICE). Bipolar disorder: assessment and management: Clinical guideline 185. 2014
- 69. National Voices. Supporting self-management. London: 2014. Available from: http://www.nationalvoices.org.uk/sites/www.nationalvoices.org.uk/files/supporting\_self-management.pdf
- 70. Foot, C, Gilburt, H, Dunn, P, Jabbal, J, Seale, B, Goodrich, J., et al. People in control of their own health and care: the state of involvement. London: 2014. Jan, Available from: https://www.kingsfund.org.uk/sites/default/files/field/field\_publication\_file/people-in-control-of-their-own-health-and-care-the-state-of-involvement-november-2014.pdf
- 71. Milton A, Lloyd-Evans B, Fullarton K, Morant N, Paterson B, Hindle D, et al. Development of a peer-supported, self-management intervention for people following mental health crisis. BMC Res Notes. 2017; 10:1–18. [PubMed: 28057050]




Figure 1. PRISMA flowchart




Figure 2. Cochrane Risk of Bias Summary

Table 1

# Study population and design

Time points† (in weeks) Comparator Sample Characteristics Tres

			Sample Characteristics	acteristics		Comparator	Time points' (in weeks)	(in weeks)
Study ID	Setting	Age	N Total/Int	Gender % Female	Diagnosis‡ (% of sample)	Intervention/Control	Post-treatment	Follow up
Freatment As Usual								
ATKINSON 1996 22	UK, Community	NR	146/73	37	SZ 100%	Education groups for People with Schizophrenia Control: TAU (Wait List Control)	20	32
BARBIC 2009 23	Canada, Community	45	33/16	33	SZ 100%	Recovery Workbook Control: TAU	12	NR R
CHIEN 2013 24	Hong Kong, Community	26	96/48	45	SZ 100%	Mindfulness-Based Psychoeducation Program (MBPP) Control: TAU	NR	37; 102 *
CHEN 2014 25	Hong Kong, Community	26	107/36	43	%2 100%	Mindfulness-Based Psychoeducation Program (MBPP) Control: TAU & Active control (basic psychoeducation)	25	52
CHIEN 2017 26	HK, China, Taiwan, Community	26	342/114	37	%001 ZS	Mindfulness-Based Psycheeducation Group Program (MBGP) Control: TAU & Active control (basic psychoeducation)	25	50; 76*; 128
COOK 2011 27–29	USA, Community	46	555/276	99	SZ: 21% BP: 38% MDD: 25%; Other: 15%	Wellness Recovery Action Planning (WRAP) Control: TAU	14	40
COOK 2012 30,31	USA, Community	43	428/212	56	SZ: 21%; BP:40%; MDD:18%; Other: 8.6%	Building Recovery of Individual Dreams and Goals through Education and Support (BRIDGES) Control: TAU	14	40
DALUM 2018 32,33	Denmark, Community	43	198/99	45	SZ: 76%; BP: 24%	Illness Management and Recovery program Control: TAU	39	NR
FARDIG 2011 34	Sweden Outpatient	40	41/21	46	SZ 100%	Illness Management and Recovery program Control: TAU	39	91

			Sample Characteristics	acteristics		Comparator	Time points <sup>†</sup> (in weeks)	(in weeks)
Study ID	Setting	Age	N Total/Int	Gender % Female	Diagnosis <sup>‡</sup> (% of sample)	Intervention/Control	Post-treatment	Follow up
HASSON 2007 35	Israel Inpatient	35	210/119	35	SZ: 84%; BP: 3%; P: 3%; Other: 3%	Illness Management and Recovery program Control: TAU	35	NR
LEVITT 2009 36	USA, Community	54	104/54	37	SZ: 32%; BP:12%; P:6%; MDD:43; Other: 7%	Illness Management and Recovery program (IMR) Control: TAU (Wait List Control)	22	72
LIN 2013 37	Taiwan, Inpatient	35	97/48	36	SZ 100%	Adapted Illness Management and Recovery program (IMR) Control: TAU	.03	7
MONROE-DEVITA 2018 38	USA, Community	4	101/53	41	SZ:81%; BP: 19%	Illness Management and Recovery program Control: TAU (Assertive Community Treatment)	26; 52 *	NR
PERRY 1999 39	UK, Outpatient	45	69/34	89	BP 100%	Teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment Control: TAU	NR	26, 52 *, 78
SAJATOVIC 2009 40	USA, Community	41	164/84	62	<b>BP</b> 100%	Life Goals Program Control: TAU	NR	13; 26; 52*
SALYERS 2010 41	USA, Community	42	324/183	46	P: 55%; BP:10%; Other:17; missing: 18%	Ilhess management and Recovery program (IMR) Control: TAU	52	104
SHON 2002 42	Korea, Outpatient	33	40/20	42	SZ: 55%; P: 15% Other: 29%	Self-Management education program Control: TAU	12	NR
SMITH 2011 43	UK, Community	4	50/24	62	<b>BP</b> 100%	Beating Bipolar Control: TAU	NR	43
TAN 2017 44	Singapore	4	50/25	62	SZ: 86%; BP: 8%; MDD: 2%; other: 4%	Illness management and Recovery program (IMR) Control: TAU	26; 52 *	104
TODD 2014 45,46	UK, Community	43	122/61	72	BP 100%	Living with Bipolar (LWB) Control: TAU (Wait List Control)	13; 26*	NR R
TORRENT 2013 47	Spain, Outpatient	40	268/82	N. R.	BP 100%	Psychoeducation + TAU (used in Colom 2003) Study had 3 arms (intervention in original study Functional Remediation) Control: TAU	21	NR

			Sample Characteristics	ıcteristics		Comparator	Time points <sup>†</sup> (in weeks)	(in weeks)
Study ID	Setting	Age	N Total/Int	Gender % Female	Diagnosis <sup>‡</sup> (% of sample)	Intervention/Control	Post-treatment	Follow up
VAN GESTELTIMMERMANS 2012 48	Netherlands, Outpatient	4	333/168	99	PD: 31% P: 33%; other: 36%	Intervention: "Recovery Is Up to You" Control: TAU	13	26
VREELAND 2006 49	USA, Outpatient	NR	71/40	55	SZ 100%	Team Solutions Control: TAU	24	NR
WANG 2016 50	Hong Kong, Community	24	138/46	48	%Z 100%	Mindfulness-Based Psychoeducation Group Program (MBGP) Control: TAU & Active control (basic psychoeducation)	25	50
ZHOU 2014 51	China, Community	35	201/103	47	SZ 100%	Modules of the UCLA Social & Independent Living Skills Program Control: TAU	26	130
Active Control								
ANZAI 2002 52	Japan, Inpatient	47	32/16	25	%001 ZS	Social and Independent Living Skills Program-Community Re- entry Module Active Control-Conventional occupational rehabilitation program	6	52
CHAN 2007 53	Hong Kong, Inpatient	36	81/44	0	%2 100%	Transforming Relapse and Instilling Prosperity (TRIP) Active Control - traditional ward occupational therapy (WOT) program	NR	54
COLOM 2003 54,55	Spain, Outpatient	NR	120/60	63	BP 100%	Psychoeducation + TAU Active Control: Unstructured support group	21	104*; 260
COOK 2013 56	USA, Community	46	143/72	50	SZ: 26%; BP 31%; MDD:27%; Other: 16%	Wellness Recovery Action Planning (WRAP) Active Control: Choosing Wellness: Healthy Eating Curriculum 9x2.5hr sessions	6	35
ECKMAN 1992 20	USA, Outpatient	40	41/20	0	%Z 100%	Social and Independent Living Skills Program-Medication and Symptom Self-management modules Active Control: Supportive Group Psychotherapy	26	78
KOPELOWICZ 1998 21,57	USA, Inpatient	35	59/28	29	SZ 100%	Community re-entry program	NR	S

Study ID Set		מ	Sampie Characteristics	cret Bures		•		(
	Setting	Age	N Total/Int	N Total/Int Gender % Female	Diagnosis‡ (% of sample)	Intervention/Control	Post-treatment	Follow up
						Active Control: Occupational therapy group		
PROUDFOOT 2012 58,59 Australia,	Australia, Outpatient	N R	419/139	70	BP 100%	Online Bipolar Education Program (BEP) + email support from expert patients known as Informed Supporters Active Control: Online Bipolar Education Program (BEP)	NR	26
SALYERS 2014 60 USA, Cc	USA, Community	84	118/60	20	SZ: 100%	Illness Management and Recovery (IMR) Active Control: unstructured problem-solving group	39	78
SCHAUB 2016 61 Germany	Germany, Inpatient	34	196/100	47	SZ: 96%; P:4%	Group-based Coping Oriented Program (COP) Active Control: Supportive group treatment	∞	52*;104
WIRSHING 2006 62 USA, I	USA, Inpatient	46	94/NR	2	%2 100%	Modified Community Re-Entry Program (CREP) Active Control: Illness Education Class	NR	53
XIANG 2006 63 China, C	China, Outpatient	39	96/48	51	%27 100%	Social and Independent Living Skills Program-Community re- entry module Active Control: Supportive counselling	∞	33
XIANG 2007 64 China,	China, Inpatient	39	103/53	53	%SZ 100%	Social and Independent Living Skills Program-Community re- entry module Active Control: Group psychoeducation program	4	26; 56 *; 78; 108

\* Time point used in meta-analysis.

 $<sup>\</sup>sp{\tau}^{T}$  Time point of data collection in weeks post randomisation.

<sup>\*</sup>Abbreviations: INT: Self-management Intervention group; SZ: schizophrenia or schizoaffective disorder; BP: bipolar disorder; P: psychosis; MDD: major depressive disorder; PD: personality disorder. NR: Not reported. TAU: Treatment as Usual. Int: intervention.

# Table 2

# Intervention characteristics organised by proposed typology

Study ID	Format	Facilitator	# Sessions	Duration (wks)	Session Length (hrs)	Dose (hrs)†	Intervention Name & Description
Illness Management and Compliance Interventions	Compliance Intervention	su					
ATKINSON 1996 22	Group	Clinician	20	20	1.5	30	Education group Sessions alternated between an information session (short presentation and discussion) followed by a problemsolving session. Patients were given a manual outlining the content of the sessions, which included: The meaning of schizophrenia to the individual, Current understandings and treatment for schizophrenia, identifying early signs of relapse and problem solving around managing relapse, symptoms, medication & side effects. Problem solving around relationships with friends and family, teaching social skills and stress management, and rehabilitation and linking in to community resources.
CHAN 2007 53	Group	Clinician	10	2	8.0	∞	Transforming Relapse and Instilling Prosperity (TRIP) Utilizes strategies from IMR however is not a direct derivative of the program. TRIP is an intensive, ward-based illness management program aims to decrease treatment non-compliance and improve patient's insight and health through didactic teaching of information about their illness and open discussion of adaptive life and coping skills. Sessions cover two categories i) illness orientated (mental health, medication management, relapse prevention planning, symptom management) and ii) health orientated (emotion management, rehabilitation resources, healthy living, stress management).
DAL UM 2018 32,33	Group	Clinician	39	39	-	39	Illness Management and Recovery (IMR) Program Follows the standardized curriculum-based approach of IMR as described below in Fardig 2011 but with an additional 11th module on healthy living lifestyles.
FARDIG 2011 34	Group	Clinician	40	40	_	40	Illness Management and Recovery (IMR) Program Is a clinician led, curriculum-based program for service users with SMI. Teaches evidence-based techniques for improving illness self-management: psychoeducation, cognitive-behavioural approaches to medication adherence, relapse prevention, social skills training (e.g., to enhance social support), coping skills training

Study ID	Format	Facilitator	# Sessions	Duration (wks)	Session Length (hrs)	Dose (hrs)†	Intervention Name & Description
							(e.g., for persistent symptoms). Overall aim is to help clients leam about mental illnesses and strategies for treatment; decrease symptoms; reduce relapses and rehospitalisation; and make progress toward goals and toward recovery.
HASSON 2007 35	Group	Clinician	35	35		35	Program Follows the standardized curriculum-based approach of IMR. Educational handouts that are a central part of the Illness Management and Recovery program were translated into Hebrew and adapted for use in Israel.
LEVITT 2009 36	Group	Clinician	40	20		40	Illness Management and Recovery (IMR) Program The standard IMR program was delivered to those living in supportive housing.
LIN 2013 37	Group	Clinician	ø	m	1.5	o.	Adapted Illness Management and Recovery (IMR) Program Adapted IMR to fit in-patient acute care setting with the primary focus on symptom and medication management, while maintaining a recovery perspective. The adapted IMR program was based on three abbreviated modules from the original IMR program: Practical Facts about Schizophrenia, Using medication Effectively, and Coping with Problems and Persistent Symptoms. The IMR sessions usually started during the third week of hospitalization. Individuals who were discharged from the hospital before completing the adapted IMR program were invited to complete it. Brief essays about recovery written by individuals who had completed the adapted MR program were also included.
MONROE-DEVITA 2018 38	Group & individual	Clinician	52	52	-	52	Program  This study assessed the effectiveness of IMR when delivered to those receiving Assertive Community Treatment. Follows the standardized curriculum-based approach of IMR but with an additional 11th module on healthy living lifestyles.
SALYERS 2010 41	Individual and group	Clinician + Peer	43	43	-	43	Illness Management and Recovery (IMR) Program This study assessed the effectiveness of IMR when delivered to those receiving Assertive Community Treatment.
SALYERS 2014 60	Group	Clinician	39	39	П	39	Illness Management and Recovery (IMR) Program Standard program

Study ID SHON 2002 42	Format Group	Facilitator Clinician	# Sessions	Duration (wks)	Session Length (hrs)	Dose (hrs) <sup>†</sup>	Intervention Name & Description Medication and Symptom Management Education program
							Sessions covered the following key areas: six sessions covered introduction of the psychiatric disorders; recognising symptoms and a variety of coping strategies, 3 sessions reinforcing knowledge concerning medication use and side effects, and 3 sessions covering relapse warning symptoms and coping skills and prevention strategies. Utilised a range of teaching, video vignettes, and small group discussions.
TAN 2017 44	Group	Clinician	26	52	-	26	Adapted Illness Management and Recovery (IMR) Program Eight of the ten IMR modules were used and adapted to the local setting. The two excluded modules covered the US mental health system and addiction and were deemed not applicable to this setting.
VREELAND 2006 49	Group	Clinician	96	24	1	96	Team Solutions Program Group based intervention consisting of three, eight-week modules covering the following topics and workbooks: i) Understanding Your Illness and Recovering From Schizophrenia; ii) Understanding Your Treatment and Getting the Best Results From Your Medication; and iii) Helping Yourself Prevent Relapse and Avoiding Crisis Situations. This program was developed by pharmaceutical company Elli Lily.
Bipolar specific illness management	nagement						
COLOM 2003 54,55	Group	Clinician	21	21	1.5	32	Manual de Psicoeducacion en Tastornos Bipolares Aims to prevent recurrences and reduce time spent ill. Addresses four main issues: illness awareness, treatment compliance, early detection of prodromal symptoms and recurrences and life style regularity through talk on topic of session, exercise related to topic and active discussion.
TORRENT 2013 47	Group	Clinician	21	2	1.5	31.5	Psychoeducation based on Manual de Psicoeducacion en Tastornos Bipolares This psychoeducacion intervention (based on Colom, 2003) aimed to prevent recurrences of bipolar illness by improving four main issues: illness awareness, treatment adherence, early detection of prodromal symptoms of relapse, and lifestyle regularity. Note: study has three arms-Functional remediation, psychoeducation and treatment as usual. Functional remediation arm was not included in this analysis as it does not meet inclusion criteria.

used to enhance learning and personalise the content, and could be down-loaded or printed out. Case studies and worked examples, written by service users were used extensively to reduce perceived isolation through shared experience. A mood checking tool was available for participants to help them identify major changes in their mood. Participants receive information about the most appropriate modules, given their mood

and psychoeducation. The intervention aims to help people to: increase their knowledge, self-esteem and self-efficacy around managing bipolar in order to pursue personally meaningful recovery goals. Ten interactive modules were developed: (1) Recovery & Me;(2) Bipolar &Me; (3) Self-management &Me; (4) Medication & Me; (5) Getting to Know Your Mood Swings; (6) Staying well with Bipolar; (7) Depression & Me; (8) Hypomania & Me; (9) Talking about my diagnosis; and (10) Crisis &Me. Worksheets were

the principles of Cognitive Behavioural Therapy

Study ID	Format	Facilitator	# Sessions	Duration (wks)	Session Length (hrs)	Dose (hrs)†	Intervention Name & Description
SAJATOVIC 2009 40	Group	Clinician	9	ý	1.25	7.5	Life Goals Program  The Life Goals Program (LGP) is a manualised, structured group psychotherapy program for individuals with bipolar disorder. It is based on behavioural principles from social learning and self-regulation theories and focuses on systematic education and individualized application of problem solving in the context of mental disorder to promote illness self-management. LGP is organized in two phases which cover illness education, management, and problem solving. Phase I is the core psychoeducational intervention. The optional phase II group sessions address goal setting and problem solving in an unstructured format.
SMITH 2011 43	Individual	Computer	8.5	7.1	ž	Υ/X	Beating Bipolar  The key areas covered in the package are: (i) the accurate diagnosis of bipolar disorder; (ii) the causes of bipolar disorder; (iii) the role of medication; (iv) the role of lifestyle changes; (v) relapse prevention and early intervention; (vi) psychological approaches; (vii) gender-specific considerations, and (viii) advice for family and carers. Online modules were required to be completed in sequential order and throughout the trial there was an opportunity for participants in the intervention group to discuss the content of the material with each other within a secure, moderated discussion forum.
TODD 2014 45,46	Individual	Computer	10	26	NR	N/A	Living with Bipolar (LWB) LWB is an online interactive recovery informed self-management intervention, broadly based on

Intervention Name & Description	symptoms. In line with the recovery agenda participants were given access to all aspects of the intervention and encouraged to use it as and when they felt appropriate.	Online Bipolar Education Program (BEP) + Informed Supporters (email support from expert patients)  The online psychoeducation program consisted of topics covering causes of bipolar disorder, diagnosis, medications, psychological treatments, omega-3 for bipolar disorder, wellbeing plans, and the importance of support networks. It was supplemented by email-based coaching and support from 'Informed Supporters' (i.e. peers) to answer specific questions or to provide examples of how to apply the education material to their everyday lives. Emails focused on effective selfmanagement across three domains: medical, emotional and role management, and were linked to the content of the online psychoeducation program. Questions of a clinical nature were referred to suitable clinicians.	Teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment  Treatment and the system relapses and training the patient to systematically identify the idiosyncratic nature and timing of their prodromal symptoms of manic or depressive relapse. Diaries were kept to distinguish symptoms associated with normal mood variation from prodromes. Once prodromes had been recognised by the patient, an action plan was created and rehearsed (such as ways to seek early treatment from a professional). The full relapse plan of warning and action stage prodromal symptoms for manic and depressive relapse with the plan for seeking treatment was recorded on a card in laminated plastic, which was carried by the patient.		SILS - Community Re-entry Module The Community Re-entry Module consists of sessions on medication management, warning signs of relapse and how to develop and implement an emergency plan to deal with relapse, how to find and secure housing and continuing psychiatric care in the community, and how to reduce stress and promote coping after discharge. The conventional program emphasizes
Dose (hrs) <sup>†</sup>		4	0		18
Session Length (hrs)		0.5	0.75		1
Duration (wks)		∞	9		6
# Sessions		∞	11.97		18
Facilitator		Computer and Peer email	Clinician		Clinician
Format		Individual	Individual	rom Ward	Group
Study ID		PROUDFOOT 2012 58,59	PERRY 1999 39	Transition to Community from Ward	ANZAI 2002 52

Study ID	Format	Facilitator	# Sessions	Duration (wks)	Session Length (hrs)	Dose (hrs)	Intervention Name & Description
							arts and crafts, reality-orientation groups, and work assignments in the hospital.
ECKMAN 1992 20	Group	Clinician	52	26	1.5	78	SILS- Medication and Symptom management modules Utilised two modules from the UCLA Social and Independent Living Skills Program. Medication and Symptom Self-management modules
KOPELOWICZ 1998 21,57	Group	Clinician	∞	-	0.75	vo	SILS - Community re-entry program Based on the UCLA Social and Independent Living Skills Modules and modified for use in the rapid-turnover, "crisis" operations of a typical acute psychiatric inpatient facility. Sessions focused on preparing participants for discharge through teaching knowledge and skills to understand their disorders and the medications that control it, to develop an aftercare treatment plan by identifying problems, specifying remedial and maintenance services, and linking with service providers, teaching skills to avoid illicit drugs, cope with stress, organize a daily schedule, and make and keep appointments with service providers.
ZHOU 2014 51	Group	Clinician	78	26	2	25	modules  The Medication and Symptom management modules  The Medication Management and Symptom Management Modules of UCLA program were delivered. Additionally, at the end of the intervention, participants were given a selfmanagement check-list journal (which monitored medication adherence, sleep, side effects, residual symptoms and signs of relapse) and the main caregiver was asked to provide guidance on the process. Participants in the intervention group attended monthly self-management group meetings (for 24 months) where community mental health workers checked and evaluated their journals.
WIRSHING 2006 62	Group	Clinician	∞	-	_	∞	Modified Community Re-Entry Program (CREP) Based on the UCLA Community re-entry modules modified to be administered during brief hospitalizations to address the immediate needs of a patient who is transitioning back into the community.
XIANG 2006 63	Group	Clinician	16	∞	-	16	SILS - Community Re-entry Module Chinese version of the community re-entry module.
XIANG 2007 64	Group	Clinician	16	4	-	16	SILS-Community Re-entry Module Chinese version of the community re-entry module

Study ID	Format	Facilitator	# Sessions	Duration (wks)	Session Length (hrs)	Dose (hrs)†	Intervention Name & Description
	-management						
BARBIC 2009 23	Group	Peer	12	12	2	24	The Modified Recovery Workbook program Training uses combination of teaching, group discussion and practical exercises, complemented by a workbook for use between sessions. Uses an educational process to increase awareness of recovery, increase knowledge and control of the illness, increase awareness of the importance and nature of stress, enhance personal meaning and sense of potential, build personal support, and develop goals and plans of action. *Note: does not include strategies for medication management
COOK 2013 56	Group	Peer	σ.	o.	2.5	22.5	Wellness Recovery Action Planning (WRAP) Group sessions consisted of lectures, individual and group exercises, personal sharing and role modelling, and voluntary homework to practice using and refining one's WRAP plan between groups. The content of each session is described fully elsewhere (Cook, Copeland, Jonikas et al., 2012), and consisted of; (a) the key concepts of WRAP and recovery, (b) personalized strategies to maintain well-being, (c) daily maintenance plans with simple and affordable tools to foster daily wellness, (d) advance planning to proactively respond to self-defined symptom riggers, (e) early warning signs that a crisis is impending and advance planning for additional support during these times, (f) advance crisis planning to identify preferred treatments and supporters when in acute phases of the illness, and (g) post crisis planning to resume daily activities and revise one's WRAP plan if needed.
COOK 2011 27–29	Group	Peer	∞	∞	2.5	20	Wellness Recovery Action Planning (WRAP) Behavioural health illness self-management intervention where participants create an individualized plan to achieve and maintain recovery by learning to utilize wellness maintenance strategies, identify and manage symptoms and crisis triggers, and cope with psychiatric crises during and following their occurrence. Instructional techniques promote peer modelling and support by using personal examples from peer facilitators and students' lives to illustrate key concepts of self- management and recovery.
COOK 2012 30,31	Group	Peer	∞	∞	2.5	20	Building Recovery of Individual Dreams and Goals through Education and Support (BRIDGES)  Course topics included recovery principles and stages; structured problem-solving and

Study ID	Format	Facilitator	# Sessions	Duration (wks)	Session Length (hrs)	Dose (hrs) <sup>†</sup>	Intervention Name & Description
							communication skills training; strategies for building interpersonal and community support systems; brain biology and psychiatric medications; diagnoses and related symptom complexes; traditional and non-traditional treatments for SMI; and relapse prevention and coping skills.
VAN GESTEL- TIMMERMANS 2012 48	Group	Peer	12	21	6	42	"Recovery Is Up to You" Course  Trained peer instructors (at an advanced state of their recovery process) were employed to facilitate this group intervention, with discussion and skills practice. Participants used a standardized workbook that covered recovery. Perlated themes: the meaning of recovery to participants, personal experiences of recovery, personal desires for the future, making choices, goal setting, participation in society, roles in daily life, personal values, how to get social support, abilities and personal resources, and empowerment and assertiveness. Important elements of the course were the presence of role models, psychoeducation and illness management, learning from other's experiences, social support, and homework assignments.
Coping Oriented Self-Management	nagement						
CHIEN 2013 24	Group	Clinician	12	24	2	24	Mindfulness-Based Psychoeducation Program (MBPP)  The program is a psychoeducational program that addresses patients' awareness and knowledge of schizophrenia and builds skills for illness management. (a) phase 1: orientation and engagement, empowerment and focused awareness of experiences, bodily sensations/ thoughts and guided awareness exercises and homework practices; (b) phase 2: education about schizophrenia care, intentionally exploring and dealing with difficulties regarding symptoms and problem-solving practices; and (c) phase 3: behavioural rehearsals of relapse prevention strategies, accessible community support resources and future plans.
CHIEN 2014 25	Group	Clinician	12	24	2	24	Mindfulness-Based Psychoeducation Program (MBPP) As described above in Chien, 2013
CHIEN 201726	Group	Clinician	12	24	2	24	Mindfulness-Based Psychoeducation Group Program (MBGP) As described above in Chien, 2013. Name of intervention changed to MBGP, but contents of intervention appear to be the same.

Intervention Name & Description	Group-based Coping Oriented Program (COP) COP seeks to improve understanding of the illness and its treatment, to teach coping strategies for specific stressors and symptoms, to activate the use of internal and external resources, and to enhance self-confidence and hope. COP combines elements of illness management with cognitive behavioural therapy for psychosis. Includes psychoeducation, cognitive-behavioural teaching principles (e.g., cognitive restructuring, role playing, problem solving). COP focused on topics of greatest concern to patients, such as symptommanagement (e.g., coping with anxiety and positive symptoms), managing stress (stress-management including mindfulness and problem solving), building up rewarding activities, time management, social skills (e.g., dealing with relatives, getting to know people), reintegration into the workplace, and providing information about outpatient services. In early groups, participants identified specific distressing symptoms for which coping strategies were selected and taught.	Mindfulness-Based Psychoeducation Group Program (MBGP) As described above in Chien, 2013. Name of intervention changed to MBGP, but contents of intervention appear to be the same.
Dose (hrs) <sup>†</sup>	vs	24
Duration (wks) Session Length (hrs)	1.25	6
	7	24
# Sessions	12	12
Facilitator	Clinician	Clinician
Format	Group	Group
Study ID	SCHAUB 2016 61	WANG 201650

NR - Not reported

#Description of intervention, with assumption that meets 4 criteria (\*with exception of Barbic, 2009).

Analysis of Self-Management Intervention (SM) for people with severe mental illness compared to control (active or TAU) (random-effects Table 3 model)

	Outcome	Time of data collection	Trials (k)	Participants SM/control (n)	Estimate	Summary of estimate [95% CI]	Z, p	Heterogeneity Q test	I <sup>2</sup> (%)
		End of treatment	17	912/1067	SMD	-0.43 [-0.63, -0.22]	4.12, <i>p</i> <.0001*	Q = 72.84, p < 0.0001	787
Br J I	(1) Iotal Symptoms	Follow-up	13	676/844	SMD	-0.88 [-1.19, -0.57]	5.52, p<.0001*	Q = 82.69, p < 0.0001	87 <sup>†</sup>
Psychi		End of treatment	∞	372/507	SMD	-0.22 [-0.51, 0.07]	1.50, <i>p</i> = 0.13	Q = 26.09, p=0.0005	73 <i>†</i>
	Fosiuve symptoms	Follow-up	9	312/459	SMD	-0.61 [-1.03, -0.19]	$2.86, p = 0.004^*$	Q=33.27, p<0.0001	857
swoodwa's and the same of the		End of treatment	6	457/590	SMD	-0.26 [-0.47, -0.05]	2.44, <i>p</i> = 0.01 *	Q=19.62, $p=0.01$	597
manus	negative Symptoms	Follow-up	7	378/523	SMD	-0.51 [-0.82, -0.21]	$3.28, p = 0.001^*$	Q=26.50, $p$ =0.0002	77 <i>†</i>
script;	V	End of treatment	ĸ	230/222	SMD	-0.26 [-0.51, -0.01]	$2.04, p = 0.04^*$	Q = 6.69, p = 0.15	40
availal	Affective Symptoms (Depression/Anxiety)	Follow-up	9	475/489	SMD	-0.19 [-0.33, -0.04]	$2.43, p = 0.02^*$	Q = 5.91, $p = 0.31$	15
ble in l	(2) <b>Mean</b> number of readmissions to acute	End of treatment	ĸ	315/456	SMD	-0.39 [-0.89, 0.11]	1.52, <i>p</i> =0.13	Q = 38.72, p < 0.0001	±06
PMC 2	care	Follow-up	'n	257/398	SMD	-0.92 [-1.63, -0.21]	$2.53, p = 0.01^*$	Q = 57.74, p < 0.0001	937
	Total number of patients in each group	End of treatment	2	104/147	RR	0.84 [0.48, 1.46]	0.63, p = 0.53	Q = 0.72, p=0.40	0
Kelapse Wovem	readmitted to acute care	Follow-up	10	416/473	RR	0.75 [0.51, 1.08]	1.54, $p = 0.12$	$Q=15.05, p=0.09^{7}$	40
ıber 01	1	End of treatment	9	359/543	SMD	-0.26 [-0.50, -0.02]	$2.08, p = 0.04^*$	Q = 10.77, p = 0.03	637
l <b>.</b>	Length of admission to acute care	Follow-up	7	350/558	SMD	-0.68 [-1.10, -0.25]	$3.12, p=0.002^*$	Q = 49.76, p < 0.0001	488
	(9) D	End of treatment	11	507/506	SMD	-0.62 [-1.03, -0.22]	$3.03, p=0.002^*$	Q=89.3, p<0.0001	\$68 £
	(3) Kecovery - 10tal	Follow-up	7	543/591	SMD	-0.81 [-1.40, -0.22]	$2.68, p = 0.007^*$	$Q = 105.09 \ p < 0.0001$	947
Recovery	D	End of treatment	3	187/159	SMD	-1.44 [-2.97, 0.08]	1.86, $p = 0.06$	Q = 44.89, p<0.0001	496
	recovery - Empowerment	Follow-up	2	278/260	SMD	-0.25 [-0.43, -0.07]	$2.68, p = 0.007^*$	Q = 1.13, p = 0.29	12
	Recovery- Hope	End of treatment	2	200/189	SMD	-0.18 [-0.38, 0.01]	1.81, $p = 0.07$	Q = 0.52, p = 0.47	0

Recovery - Self-Efficiency   Follow-up   3	Follow-up   3   487480   SMD   -0.24 [-0.46, -0.02]   2.16, p=0.03*   Q=5.74, p=0.06     End of treatment   4   322279   SMD   -0.34 [-0.61, -0.07]   3.18, p=0.001 *   NA     Follow-up   1   121/100   SMD   -0.34 [-0.61, -0.07]   2.50, p=0.01 *   NA     Follow-up   14   805/1000   SMD   -0.56 [-0.85, -0.28]   3.90, p=0.0001 *   Q=5.42, p=0.0001     Follow-up   14   805/1000   SMD   -0.56 [-0.85, -0.28]   3.97, p=0.0001 *   Q=121.25, p=0.0001     Follow-up   7   491489   SMD   -0.25 [-0.37, -0.12]   3.38, p=0.0007 *   Q=7.83, p=0.45     Follow-up   7   491489   SMD   -0.25 [-0.37, -0.12]   3.84, p=0.0001 *   Q=3.07, p=0.80     Follow-up   7   491489   SMD   -0.25 [-0.37, -0.12]   3.84, p=0.0001 *   Q=3.07, p=0.80     Follow-up   7   491489   SMD   -0.25 [-0.37, -0.12]   3.84, p=0.0001 *   Q=3.07, p=0.80     Follow-up   7   491489   SMD   -0.25 [-0.37, -0.12]   3.84, p=0.0001 *   Q=3.07, p=0.80     Follow-up   7   491489   SMD   -0.25 [-0.37, -0.12]   3.84, p=0.0001 *   Q=3.07, p=0.80     Follow-up   7   491489   SMD   -0.25 [-0.37, -0.12]   3.84, p=0.0001 *   Q=3.07, p=0.80     Follow-up   7   491489   SMD   -0.25 [-0.37, -0.12]   3.84, p=0.0001 *   Q=3.07, p=0.80     Follow-up   7   491489   SMD   -0.25 [-0.37, -0.12]   3.84, p=0.0001 *   Q=3.07, p=0.80     Follow-up   7   491489   SMD   -0.25 [-0.37, -0.12]   3.84, p=0.0001 *   Q=3.07, p=0.80     Follow-up   7   491489   SMD   -0.25 [-0.37, -0.12]   3.84, p=0.0001 *   Q=3.07, p=0.80     Follow-up   7   491489   SMD   -0.25 [-0.37, -0.12]   3.84, p=0.0001 *   Q=3.07, p=0.80     Follow-up   7   491489   SMD   -0.25 [-0.37, -0.12]   3.84, p=0.0001 *   Q=3.07, p=0.80     Follow-up   7   491480   SMD   -0.25 [-0.37, -0.12]   3.84, p=0.0001 *   Q=3.07, p=0.80     Follow-up   7   491480   SMD   -0.25 [-0.37, -0.12]   SMD   -0.25 [-0.37,		Recovery - Self-Efficacy	Follow-up	8	487/480		-			
4 322279 SMD -0.38 [-0.62, -0.15] 3.18, p=0.001 * Q=5.42, p=0.14  1 121/100 SMD -0.34 [-0.61, -0.07] 2.50, p=0.01 * N/A  15 884/1064 SMD -0.56 [-0.85, -0.28] 3.90, p<0.0001 * Q=121.25, p<0.0001  14 805/1000 SMD -0.20 [-1.34, -0.45] 3.97, p<0.0001 * Q=737.9, p<0.0001  7 491/489 SMD -0.25 [-0.37, -0.12] 3.38, p=0.0007 * Q=7.83, p=0.80  7 491/489 SMD -0.25 [-0.37, -0.12] 3.84, p=0.0001 * Q=3.07, p=0.80	4 322/279 SMD -0.38 [-0.62, -0.15] 3.18, p=0.001* Q=5.42, p=0.14  1 121/100 SMD -0.34 [-0.61, -0.07] 2.50, p=0.01* N/A  15 884/1064 SMD -0.56 [-0.85, -0.28] 3.90, p<0.0001* Q=121.25, p<0.0001  14 805/1000 SMD -0.26 [-1.34, -0.45] 3.97, p<0.0001* Q=737.9, p<0.0001  9 440/423 SMD -0.23 [-0.37, -0.10] 3.38, p=0.0007* Q=7.83, p=0.45  7 491/489 SMD -0.25 [-0.37, -0.12] 3.84, p=0.0001* Q=3.07, p=0.80		Recovery - Self-Efficacy				SMD	-0.24 [-0.46, -0.02]	$2.16, p = 0.03^*$	Q = 5.74, p = 0.06	657
15 884/1064 SMD -0.36 [-0.85, -0.28] 3.90, $p$ =0.001 * $Q$ =121.25, $p$ <0.0001   14 805/1000 SMD -0.90 [-1.34, -0.45] 3.97, $p$ <0.0001 * $Q$ =237.9, $p$ <0.0001   2 440/423 SMD -0.23 [-0.37, -0.10] 3.38, $p$ =0.0007 * $Q$ =7.83, $p$ =0.45   2 491/489 SMD -0.25 [-0.37, -0.12] 3.84, $p$ =0.0001 * $Q$ =3.07, $p$ =0.80	15 884/1064 SMD -0.36 [-0.85, -0.28] 3.90, p=0.01 * O=121.25, p=0.0011    14 805/1000 SMD -0.90 [-1.34, -0.45] 3.97, p=0.0001 * O=121.25, p=0.0001    9 440/423 SMD -0.23 [-0.37, -0.10] 3.38, p=0.0007 * O=7.83, p=0.45    7 491/489 SMD -0.25 [-0.37, -0.12] 3.84, p=0.0001 * O=3.07, p=0.80		Kecovery - Self-Efficacy	End of treatment	4	322/279	SMD	-0.38 [-0.62, -0.15]	$3.18, p = 0.001^*$	Q = 5.42, p= 0.14	45
15 884/1064 SMD -0.56 [-0.85, -0.28] 3.90, p<0.0001* Q=121.25, p<0.0001 14 805/1000 SMD -0.90 [-1.34, -0.45] 3.97, p<0.0001* Q=237.9, p<0.0001 9 440/423 SMD -0.23 [-0.37, -0.10] 3.38, p=0.0007* Q=7.83, p=0.45 7 491/489 SMD -0.25 [-0.37, -0.12] 3.84, p=0.0001* Q=3.07, p=0.80	15 884/1064 SMD -0.56 [-0.85, -0.28] 3.90, p<0.0001 * Q=121.25, p<0.0001   14 805/1000 SMD -0.90 [-1.34, -0.45] 3.97, p<0.0001 * Q=237.9, p<0.0001   9 440/423 SMD -0.23 [-0.37, -0.10] 3.38, p=0.0007 * Q=7.83, p=0.45   7 491/489 SMD -0.25 [-0.37, -0.12] 3.84, p=0.0001 * Q=3.07, p=0.80			Follow-up	П	121/100	SMD	-0.34 [-0.61, -0.07]	$2.50, p = 0.01^*$	N/A	N/A
14 805/1000 SMD -0.90 [-1.34, -0.45] 3.97, p<0.0001* Q = 237.9, p<0.0001  9 440/423 SMD -0.23 [-0.37, -0.10] 3.38, p=0.0007* Q=7.83, p=0.45  7 491/489 SMD -0.25 [-0.37, -0.12] 3.84, p=0.0001* Q=3.07, p=0.80	14 805/1000 SMD -0.90 [-1.34, -0.45] 3.97, p<0.0001* Q=237.9, p<0.0001 9 440/423 SMD -0.23 [-0.37, -0.10] 3.38, p=0.0007* Q=7.83, p=0.45 7 491/489 SMD -0.25 [-0.37, -0.12] 3.84, p=0.0001* Q=3.07, p=0.80			End of treatment	15	884/1064	SMD	-0.56 [-0.85, -0.28]	3.90, <i>p</i> <0.0001*	Q=121.25, <i>p</i> <0.0001	88
9 $440423$ SMD $-0.23 [-0.37, -0.10]$ $3.38, p = 0.0007$ * $Q = 7.83, p = 0.45$ 7 $491489$ SMD $-0.25 [-0.37, -0.12]$ $3.84, p = 0.0001$ * $Q = 3.07, p = 0.80$	9 $440/423$ SMD $-0.23 [-0.37, -0.10]$ $3.38, p = 0.0007^*$ $Q = 7.83, p = 0.45$ 7 $491/489$ SMD $-0.25 [-0.37, -0.12]$ $3.84, p = 0.0001^*$ $Q = 3.07, p = 0.80$	runcuoning	(4) Functioning	To11000	14	805/1000	SMD	-0.90 [-1.34, -0.45]	3.97, <i>p</i> <0.0001*	Q = 237.9, p < 0.0001	957
7 $491/489$ SMD $-0.25 [-0.37, -0.12]$ $3.84, p=0.0001*$ $Q=3.07, p=0.80$	7 $491/489$ SMD $-0.25 [-0.37, -0.12]$ $3.84, p=0.0001*$ $Q=3.07, p=0.80$			dn-wonoa					ı		
ndicates high heterogeneity: 1 <sup>2</sup> exceeds 50% and/or P value less than 0.10	ndicates high heterogeneity: I <sup>2</sup> exceeds 50% and/or P value less than 0.10		21. 13tit (2).	Fonow-up End of treatment	6	440/423	SMD	-0.23 [-0.37, -0.10]	3.38, p=0.0007*	Q = 7.83, p = 0.45	0
ndicates high heterogeneity: 1 <sup>2</sup> exceeds 50% and/or P value less than 0.10	ndicates high heterogeneity: 1 <sup>2</sup> exceeds 50% and/or P value less than 0.10	OoL	(5) Quality of Life	End of treatment Follow-up	6 7	440/423	SMD	-0.23 [-0.37, -0.10] -0.25 [-0.37, -0.12]	3.38, <i>p</i> =0.0007* 3.84, <i>p</i> =0.0001*	Q = 7.83, p = 0.45 Q = 3.07, p = 0.80	0 0
		QoL Statistically sign	(5) Quality of Life nificant finding (p<0.05)	Follow-up Follow-up	6 1	440/423	SMD	-0.23 [-0.37, -0.10] -0.25 [-0.37, -0.12]	3.38, p=0.0007 * 3.84, p=0.0001 *	Q = 7.83, p = 0.45 Q = 3.07, p = 0.80	0 0
		QoL tatistically sign ndicates high h	(5) Quality of Life  nificant finding (p<0.05)  reterogeneity: 1 <sup>2</sup> exceeds 50% and/or P val	Follow-up End of treatment Follow-up e less than 0.10	6 7	440/423	SMD	-0.23 [-0.37, -0.10] -0.25 [-0.37, -0.12]	3.38, p=0.0007 * 3.84, p=0.0001 *	Q = 7.83, p = 0.45 Q = 3.07, p = 0.80	0 0
		QoL Statistically signindicates high h	(5) Quality of Life nificant finding (p<0.05) teterogeneity: 1 <sup>2</sup> exceeds 50% and/or P val	Follow-up Follow-up Follow-up e less than 0.10	6 7	440/423	SMD	-0.23 [-0.37, -0.10] -0.25 [-0.37, -0.12]	3.38, p=0.0007 * 3.84, p=0.0001 *	Q = 7.83, p = 0.45 Q = 3.07, p = 0.80	0 0
		QoL  Statistically sign Indicates high h	(5) Quality of Life  nificant finding (p<0.05)  eterogeneity: 1 <sup>2</sup> exceeds 50% and/or P val	Follow-up Follow-up Follow-up e less than 0.10	0 1	440/423	SMD	-0.23 [-0.37, -0.10] -0.25 [-0.37, -0.12]	3.38, p=0.0007 * 3.84, p=0.0001 *	Q = 7.83, p = 0.45 Q = 3.07, p = 0.80	0 0
		QoL statistically sign ndicates high h	(5) Quality of Life  inficant finding (p<0.05)  eterogeneity: 1 <sup>2</sup> exceeds 50% and/or P val	Follow-up Follow-up Follow-up e less than 0.10	0 1	440/423	SMD	-0.23 [-0.37, -0.10] -0.25 [-0.37, -0.12]	3.38, p=0.0007 * 3.84, p=0.0001 *	Q = 7.83, p = 0.45 Q = 3.07, p = 0.80	0 0
		QoL itatistically sign	(5) Quality of Life  nificant finding (p<0.05)  eterogeneity: 1 <sup>2</sup> exceeds 50% and/or P val	Follow-up Follow-up Follow-up e less than 0.10	6 1	440/423	SMD	-0.23 [-0.37, -0.10] -0.25 [-0.37, -0.12]	3.38, p=0.0007 * 3.84, p=0.0001 *	Q = 7.83, p = 0.45 Q = 3.07, p = 0.80	0 0